Roy Lalisang

3.6k total citations
51 papers, 1.2k citations indexed

About

Roy Lalisang is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roy Lalisang has authored 51 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pediatrics, Perinatology and Child Health and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roy Lalisang's work include Childhood Cancer Survivors' Quality of Life (12 papers), Family Support in Illness (9 papers) and Ovarian cancer diagnosis and treatment (9 papers). Roy Lalisang is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (12 papers), Family Support in Illness (9 papers) and Ovarian cancer diagnosis and treatment (9 papers). Roy Lalisang collaborates with scholars based in Netherlands, United States and Belgium. Roy Lalisang's co-authors include J. B. C. M. Puylaert, S. D. J. Van Der Werf, P.H. Rutgers, S D van der Werf, Frank Hoebers, Philippe Lambin, Frans Erdkamp, Gabe S. Sonke, Annemie M.W.J. Schols and Anna C. H. Willemsen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Roy Lalisang

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roy Lalisang Netherlands	18	441	354	255	232	123	51	1.2k
Wanqing Iris Zhi United States	16	202 0.5×	49 0.1×	585 2.3×	221 1.0×	52 0.4×	40	1.2k
Whee Sze Ong Singapore	16	180 0.4×	65 0.2×	222 0.9×	199 0.9×	32 0.3×	46	614
Alexandra Easson Canada	22	799 1.8×	52 0.1×	730 2.9×	262 1.1×	54 0.4×	65	1.8k
Geert‐Jan Creemers Netherlands	22	394 0.9×	73 0.2×	781 3.1×	329 1.4×	77 0.6×	65	1.2k
John K. Petty United States	17	241 0.5×	114 0.3×	151 0.6×	120 0.5×	53 0.4×	49	716
Hélène Senellart France	19	293 0.7×	38 0.1×	862 3.4×	379 1.6×	35 0.3×	78	1.2k
Geert-Jan Creemers Netherlands	15	489 1.1×	136 0.4×	907 3.6×	376 1.6×	63 0.5×	44	1.4k
İlhan Öztop Türkiye	23	309 0.7×	47 0.1×	766 3.0×	303 1.3×	116 0.9×	106	1.4k
Kara Long Roche United States	24	721 1.6×	48 0.1×	502 2.0×	214 0.9×	73 0.6×	124	1.9k
Wendy R. Brewster United States	24	363 0.8×	50 0.1×	429 1.7×	269 1.2×	101 0.8×	77	1.9k

Countries citing papers authored by Roy Lalisang

Since Specialization

Citations

This map shows the geographic impact of Roy Lalisang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Lalisang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Lalisang more than expected).

Fields of papers citing papers by Roy Lalisang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Lalisang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Lalisang. The network helps show where Roy Lalisang may publish in the future.

Co-authorship network of co-authors of Roy Lalisang

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Lalisang. A scholar is included among the top collaborators of Roy Lalisang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Lalisang. Roy Lalisang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Janssen, Silvie H. M., Carla Vlooswijk, Rhodé M. Bijlsma, et al.. (2025). Health-related quality of life of long-term adolescent and young adult (AYA) cancer survivors compared to a matched normative population: results of the SURVAYA study. Journal of Cancer Survivorship.

Vlooswijk, Carla, Renaud Tissier, Rhodé M. Bijlsma, et al.. (2024). Exploring the interconnectedness between health-related quality of life factors among long-term adolescent and young adult cancer survivors (AYAs): a network analysis. Supportive Care in Cancer. 32(2). 104–104. 1 indexed citations

Velasco, Roser, Andreas A. Argyriou, David R. Cornblath, et al.. (2024). Repurposing chemotherapy‐induced peripheral neuropathy grading. European Journal of Neurology. 31(12). e16457–e16457. 4 indexed citations

Janssen, Silvie H. M., Carla Vlooswijk, Rhodé M. Bijlsma, et al.. (2024). Health-related conditions among long-term cancer survivors diagnosed in adolescence and young adulthood (AYA): results of the SURVAYA study. Journal of Cancer Survivorship. 19(6). 1821–1834. 4 indexed citations

Auranen, Annika, Destin Black, Vladyslav Sukhin, et al.. (2023). #540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). A11.2–A12. 2 indexed citations

Vlooswijk, Carla, Lonneke V. van de Poll‐Franse, Silvie H. M. Janssen, et al.. (2022). Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study. Current Oncology. 29(8). 5407–5425. 23 indexed citations

Bent, Martin J. van den, Linda Dirven, Roy Lalisang, et al.. (2022). “Finding my way in a maze while the clock is ticking”: The daily life challenges of adolescents and young adults with an uncertain or poor cancer prognosis. Frontiers in Oncology. 12. 994934–994934. 11 indexed citations

Westermann, Anneke M., Ingrid Boere, Petronella O. Witteveen, et al.. (2022). Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecologic Oncology. 165(2). 223–229. 31 indexed citations

Weelden, Willem Jan van, Reini Bretveld, Andrea Romano, et al.. (2021). Trends over time in the incidence and use of hormonal therapy in endometrial cancer: a population-based study in the Netherlands. International Journal of Gynecological Cancer. 31(7). 1014–1020. 3 indexed citations

10.

Greidanus, M. A., Angela G. E. M. de Boer, Angelique de Rijk, et al.. (2020). The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility. Patient. 13(5). 567–582. 11 indexed citations

11.

Timmermans, Maite, Maaike A. van der Aa, Roy Lalisang, et al.. (2018). Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecologic Oncology. 150(3). 446–450. 48 indexed citations

12.

Phillips, Michael, J. David Beatty, Renee N. Cataneo, et al.. (2014). Rapid Point-Of-Care Breath Test for Biomarkers of Breast Cancer and Abnormal Mammograms. PLoS ONE. 9(3). e90226–e90226. 47 indexed citations

13.

Hoebers, Frank, Eduardo Ríos, Esther G.C. Troost, et al.. (2013). Definitive radiation therapy for treatment of laryngeal carcinoma. Strahlentherapie und Onkologie. 189(10). 834–841. 15 indexed citations

14.

Reyners, A.K.L., Linda de Munck, Frans Erdkamp, et al.. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology. 23(11). 2896–2902. 34 indexed citations

15.

Lalisang, Roy, Frans Erdkamp, C. J. Rodenburg, et al.. (2011). Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. Breast Cancer Research and Treatment. 128(2). 437–445. 5 indexed citations

16.

Rijke, J.M. de, Leo J. Schouten, G.P.M. ten Velde, et al.. (2004). Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 46(2). 233–245. 74 indexed citations

17.

Hillen, H.F.P., Harry C. Schouten, Roy Lalisang, et al.. (2000). True. British Journal of Cancer. 82(12). 1914–1919. 5 indexed citations

18.

Rodenhuis, Sjoerd, Ronald de Wit, P.H.M. de Mulder, et al.. (1999). A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Annals of Oncology. 10(12). 1467–1474. 50 indexed citations

19.

Lalisang, Roy, J. Wils, J Burghouts, et al.. (1997). Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.. Journal of Clinical Oncology. 15(4). 1367–1376. 26 indexed citations

20.

Oostenbrugge, Robert J. van, et al.. (1996). Fatal Stroke due to Paradoxical Fat Embolism. Cerebrovascular Diseases. 6(5). 313–314. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact